Mechanisms of action of therapeutic antibodies for cancer

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 28-45

  Redman, J M ^a   Hill, E M ^a   AlDeghaither, D ^a   Weiner, L M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antibodies; Immunoconjugates; Immunotoxins

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPECIFIC ANTIBODY; CANCER ANTIBODY; CD20 ANTIBODY; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DALOTUZUMAB; DULIGOTUZUMAB; DUSIGITUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GANITUMAB; IBRITUMOMAB TIUXETAN; NECITUMUMAB; NIMOTUZUMAB; ONARTUZUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PANITUMUMAB; PERTUZUMAB; PROGRAMMED DEATH 1 RECEPTOR; RAMUCIRUMAB; SCATTER FACTOR RECEPTOR; SOMATOMEDIN RECEPTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VASCULOTROPIN; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOLOGY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; EFFECTOR CELL; ESOPHAGEAL ADENOCARCINOMA; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; NEOPLASM; PANCREAS CANCER; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; STOMACH ADENOCARCINOMA; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84939470826     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.04.002     Document Type: Review

References (300)

1. Abbas A.K., et al. Cellular and Molecular Immunology 2015, 265-288. eighth edition.
2. Agus D.B., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137.
3. Ahmadzadeh M., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
4. Ai J., Advani A. Current status of antibody therapy in ALL. British Journal of Haematology 2014, 10.1111/bjh.13205.
5. Akiyama T., et al. RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clinical & Experimental Metastasis 2010, 27:207-215.
6. Albert M.L., et al. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392:86-89.
7. AlDeghaither D., Weiner L.M. Beyond peptides and mAbs-current status and future perspectives for biotherapeutics with novel constructs. The Journal of Clinical Pharmacology 2015, 55(March (Suppl. 3)):S4-S20.
8. Alduaij W., et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011, 117:4519-4529.
9. Aleem E., et al. Upregulation of the insulin receptor and type I insulin-like growth factor receptor are early events in hepatocarcinogenesis. Toxicologic Pathology 2011, 39:524-543.
10. Amado R.G., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2008, 26:1626-1634.
11. Amanatullah D.F., et al. Giant cell tumor of bone. Orthopedics 2014, 37:112-120.
12. Antonia S.J., Shepherd F.A., Gettinger S.N., et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. Journal of Clinical Oncology: Official Journal of the American Society of Clinical 2014, 32(Suppl. 5s). (abstract no. 8024).
13. Arcila M.E., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17:1169-1180.
14. Armand P., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2013, 31:4199-4206.
15. Arruebo M., et al. Antibody-conjugated nanoparticles for biomedical applications. Journal of Nanomaterials 2009, 24.
16. Baader E., et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Research 2005, 65:7888-7895.
17. Badache A., Hynes N.E. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 2004, 5:299-301.
18. Baeuerle P.A., et al. BiTE: teaching antibodies to engage T-cells for cancer therapy. Current Opinion in Molecular Therapeutics 2009, 11:22-30.
19. Balasa B., et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways. Cancer Immunology, Immunotherapy: CII 2015, 64:61-73.
20. Barthelemy P., et al. Pertuzumab and solid tumors: perspectives. Bulletin du Cancer 2014, 101:1114-1121.
21. Bartlett N.L., et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology & Oncology 2014, 7:24.
22. Basilico C., et al. Four individually druggable MET hotspots mediate HGF-driven tumor progression. The Journal of Clinical Investigation 2014, 124:3172-3186.
23. Bean J., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:20932-20937.
24. Beatty G.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
25. Beatty G.L., et al. A phase I study of agonist CD40 monoclonal antibody (CP-870, 893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clincal Cancer Research 2013, 19:6286-6295.
26. Berard F., et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. The Journal of Experimental Medicine 2000, 192:1535-1544.
27. Berdeja H.-I.F.J.G., Chanan-Khan A., et al. Phase I study of lorvotuzumabmertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29(Suppl.). (abstract 8013).
28. Berger R., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:3044-3051.
29. Beste G., et al. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:1898-1903.
30. Beum P.V., et al. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. Journal of Immunological Methods 2004, 289:97-109.
31. Beum P.V., et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. Journal of Immunology 2011, 187:3438-3447.
32. Blanc V., et al. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17:6448-6458.
33. Bogner C., et al. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. British Journal of Haematology 2010, 148:99-109.
34. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007, 26:3629-3636.
35. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine 2012, 366:2455-2465.
36. Branstetter D.G., et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18:4415-4424.
37. Buhmann R., et al. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. Journal of Translational Medicine 2013, 11:160.
38. Burris H.A., et al. A phase I study of DNIB0600A, an antibody-drug conjugate targeting NaPi2b, in patients with non-small cell lung cancer or platinum-resistant ovarian cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2014, 32:5s.
39. Butte M.J., et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
40. Cappuzzo F., et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009, 27:1667-1674.
41. Carlotti E., et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007, 92:1127-1130.
42. Carpenter G., Cohen S. Epidermal growth factor. The Journal of Biological Chemistry 1990, 265:7709-7712.
43. Cartron G., et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004, 104:2635-2642.
44. Catania C., et al. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. Cell Adhesion & Migration 2015, 9:14-21.
45. Chan H.T., et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Research 2003, 63:5480-5489.
46. Chandarlapaty S., et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
47. Chawla S., et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. The Lancet. Oncology 2013, 14:901-908.
48. Chen J.S., et al. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 2003, 6:129-136.
49. Chen C., et al. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor. Molecular Cancer Therapeutics 2014, 13:90-100.
50. Chen S., et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunology Research 2014, 10.1158/2326-6066.CIR-14-0118.
51. Cho D.C., Sosman J.A., Sznol M., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology: Official Journal of the American Society of Clinical 2013, 32(Suppl. 5s). (abstract no. 5012).
52. Choi B.D., et al. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opinion on Biological Therapy 2011, 11:843-853.
53. Cipriani N.A., et al. MET as a target for treatment of chest tumors. Lung Cancer 2009, 63:169-179.
54. Clynes R.A., et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine 2000, 6:443-446.
55. Cragg M.S., Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004, 103:2738-2743.
56. Cretney E., et al. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunology and Cell Biology 2006, 84:87-98.
57. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nature Reviews. Immunology 2009, 9:271-285.
58. Croft M. The TNF family in T cell differentiation and function-unanswered questions and future directions. Seminars in Immunology 2014, 26:183-190.
59. Curti B.D., et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Research 2013, 73:7189-7198.
60. Cummings S.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine 2009, 361(August (8)):756-765.
61. Dabir S., et al. CD30 is a potential therapeutic target in malignant mesothelioma. Molecular Cancer Therapeutics 2015, 10.1158/1535-7163.MCT-14-0972.
62. Dawood S., Sirohi B. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer. Future Oncology 2015, 11:923-931.
63. de Weers M., et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. Journal of Immunology 2011, 186:1840-1848.
64. Delyon J., et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2013, 24:1697-1703.
65. Di Gaetano N., et al. Complement activation determines the therapeutic activity of rituximab in vivo. Journal of Immunology 2003, 171:1581-1587.
66. Dijkers E.C., et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clinical Pharmacology and Therapeutics 2010, 87:586-592.
67. Dineen S.P., et al. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2008, 8:352.
68. Ducry L., Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjugate Chemistry 2010, 21:5-13.
69. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell Research 2010, 20:34-50.
70. Elgueta R., et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunological Reviews 2009, 229:152-172.
71. Emmanouilides C., et al. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biotherapy & Radiopharmaceuticals 2002, 17:621-630.
72. Engelman J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
73. Enguita-German M., Fortes P. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World Journal of Hepatology 2014, 6:716-737.
74. Eyre T.A., et al. Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome. BMC Cancer 2015, 15:52.
75. Fan Q.W., et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 2013, 24:438-449.
76. Fanoni D., et al. New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunology Letters 2011, 134:157-160.
77. Farag S.S., et al. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004, 103:1472-1474.
78. Firer M.A., Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. Journal of Hematology & Oncology 2012, 5:70.
79. FitzGerald D.J., et al. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Research 2011, 71:6300-6309.
80. Fitzgerald J.B., et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Molecular Cancer Therapeutics 2014, 13:410-425.
81. Flieger D., et al. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cellular Immunology 2000, 204:55-63.
82. Foran J.M., et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2000, 18:317-324.
83. Forero-Torres A., et al. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Medicine 2013, 2:925-932.
84. Francisco L.M., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. The Journal of Experimental Medicine 2009, 206:3015-3029.
85. Franklin M.C., et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328.
86. Freeman G.J., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of Experimental Medicine 2000, 192:1027-1034.
87. Fuchs C.S., et al. A phase 3 randomized, double-blind placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA Trial. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2015, 10.1093/annonc/mdv027.
88. Furtado M., et al. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma-a phase II trial. British Journal of Haematology 2014, 165:575-578.
89. Gagez A.L., Cartron G. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Current Opinion in Oncology 2014, 26:484-491.
90. Gamis A.S., et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2014, 32:3021-3032.
91. Gan H.K., et al. A phase I study evaluating ABT-414 in combination with temozolamide for subjects with recurrent or unresectable glioblastoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2014, 32:5s.
92. Gao J., et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Research 2011, 71:1029-1040.
93. Gebauer M., Skerra A. Anticalins small engineered binding proteins based on the lipocalin scaffold. Methods in Enzymology 2012, 503:157-188.
94. Gedeon P.C., et al. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Review of Clinical Pharmacology 2013, 6:375-386.
95. Geoerger B., et al. Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma. European Journal of Cancer 2010, 46:3251-3262.
96. Goebl N.A., et al. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Molecular Biology of the Cell 2008, 19:5490-5505.
97. Goetsch L., et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. International Journal of Cancer. Journal international du cancer 2005, 113:316-328.
98. Gul N., et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. The Journal of Clinical Investigation 2014, 124:812-823.
99. Guo F., et al. Breaking the one antibody-one target axiom. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:11009-11014.
100. Guo Z., et al. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS ONE 2014, 9:e89350.
101. Gutbrodt K.L., et al. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Science Translational Medicine 2013, 5. 201ra118.
102. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013, 122:3723-3734.
103. Haluska P., et al. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2014, 20:4747-4757.
104. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Seminars in Cancer Biology 1999, 9:67-81.
105. Harari P.M., et al. Biology of interactions: antiepidermal growth factor receptor agents. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2007, 25:4057-4065.
106. Hassan R., et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Science Translational Medicine 2013, 5. 208ra147.
107. He X., et al. GD3 expression by cultured human tumor cells of neuroectodermal origin. Acta Neuropathologica 1989, 79:317-325.
108. Heeren A.M., et al. High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer. Cancer Immunology Research 2015, 3:48-58.
109. Heery O.S.G.C.R., Madan R.A., et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical 2014, 32(Suppl. 5s). (abstr 3064).
110. Henry D., et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 2014, 22:679-687.
111. Herbst G.M.R.S., Fine G.D., et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical 2013, 31(Suppl.). (abstr 3000).
112. Hernandez-Ilizaliturri F.J., et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2003, 9:5866-5873.
113. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010, 363:711-723.
114. Hoffmann T.K., et al. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Research 2000, 60:3542-3549.
115. Hoffmeyer F., et al. The high-affinity Fc gamma RI on PMN: regulation of expression and signal transduction. Immunology 1997, 92:544-552.
116. Holland P.M. Death receptor agonist therapies for cancer, which is the right TRAIL?. Cytokine & Growth Factor Reviews 2014, 25:185-193.
117. Hsu H., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:3540-3545.
118. Huang L., et al. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. The American Journal of Pathology 2000, 156:761-767.
119. Huang F., et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Research 2009, 69:161-170.
120. Huang G.S., et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16:2999-3010.
121. Huang X., et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Research 2010, 70:1204-1214.
122. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. The New England Journal of Medicine 2007, 357:39-51.
123. Huehls A.M., et al. Bispecific T-cell engagers for cancer immunotherapy. Immunology and Cell Biology 2014, 10.1038/icb.2014.93.
124. Iguchi H., et al. Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours. Investigational New Drugs 2015, 33:194-200.
125. Ikemoto N., et al. Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:10506-10510.
126. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nature Reviews. Cancer 2006, 6:714-727.
127. Ishida Y., et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO Journal 1992, 11:3887-3895.
128. Ishimura N., et al. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. American Journal of Physiology. Gastrointestinal and Liver Physiology 2006, 290:G129-G136.
129. Jain R.K. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Seminars in Oncology 2002, 29:3-9.
130. Jin Q., Esteva F.J. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. Journal of Mammary Gland Biology and Neoplasia 2008, 13:485-498.
131. Junutula J.R., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotechnology 2008, 26:925-932.
132. 131I]anti-B1 (anti-CD20) antibody. The New England Journal of Medicine 1993, 329:459-465.
133. Karapetis C.S., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine 2008, 359:1757-1765.
134. Khalil M., Vonderheide R.H. Anti-CD40 agonist antibodies: preclinical and clinical experience. Update on Cancer Therapeutics 2007, 2:61-65.
135. Kim R. Cetuximab and panitumumab: are they interchangeable?. The Lancet. Oncology 2009, 10:1140-1141.
136. Knox S.J., et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2000, 6:406-414.
137. Koene H.R., et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997, 90:1109-1114.
138. Kohrt H.E., et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011, 117:2423-2432.
139. Kohrt H.E., et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. The Journal of Clinical Investigation 2012, 122:1066-1075.
140. Kohrt H.E., et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014, 123:678-686.
141. Koide A., et al. The fibronectin type III domain as a scaffold for novel binding proteins. Journal of Molecular Biology 1998, 284:1141-1151.
142. Koide A., et al. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. Journal of Molecular Biology 2012, 415:393-405.
143. Kreitman R.J., et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30:1822-1828.
144. Krop I.E., et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30:3234-3241.
145. Krop I.E., et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet. Oncology 2014, 15:689-699.
146. Kuan C.T., et al. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocrine-related Cancer 2001, 8:83-96.
147. Kubota T., et al. Engineered therapeutic antibodies with improved effector functions. Cancer Science 2009, 100:1566-1572.
148. Lanzavecchia A. Immunology. Licence to kill. Nature 1998, 393:413-414.
149. Lefebvre M.L., et al. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. Journal of Immunotherapy 2006, 29:388-397.
150. Lenschow D.J., et al. CD28/B7 system of T cell costimulation. Annual Review of Immunology 1996, 14:233-258.
151. Li S., et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
152. Li Y., et al. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. Journal of Immunology 2007, 179:4263-4271.
153. Lim S.H., Levy R. Translational medicine in action: anti-CD20 therapy in lymphoma. Journal of Immunology 2014, 193:1519-1524.
154. Lim S.H., et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011, 118:2530-2540.
155. Linsley P.S., et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1:793-801.
156. Liontos M., et al. Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. OncoTargets and Therapy 2014, 7:1837-1845.
157. Liu J.P., et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75:59-72.
158. Liu Y., et al. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clinical Immunology 2008, 129:471-481.
159. Liu D., et al. Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer. Oncotarget 2015, 6(February (6)):4274-4285.
160. Loffler A., et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000, 95:2098-2103.
161. LoRusso P.M., et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17:6437-6447.
162. Lutterbuese R., et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. Journal of Immunotherapy 2009, 32:341-352.
163. Ma P.C., et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Reviews 2003, 22:309-325.
164. Maloney E.K., et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Research 2003, 63:5073-5083.
165. Maric G., et al. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. OncoTargets and Therapy 2013, 6:839-852.
166. Marks J.D., et al. Human antibody fragments specific for human blood group antigens from a phage display library. Biotechnology (N.Y.) 1993, 11:1145-1149.
167. Massimino M., et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood,. Journal of Neuro-oncology 2014, 118:305-312.
168. Mattoo A.R., et al. Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P. PLoS ONE 2013, 8:e75576.
169. Melero I., et al. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2013, 19:997-1008.
170. Mendler C.T., et al. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. mAbs 2015, 7:96-109.
171. Molhoj M., et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Molecular Immunology 2007, 44:1935-1943.
172. Monk B.J., et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. The Lancet. Oncology 2014, 15:799-808.
173. Moore G.L., et al. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2010, 2:181-189.
174. Moore P.A., et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011, 117:4542-4551.
175. Moran T., et al. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. Experimental Hematology & Oncology 2014, 3:26.
176. Morecki S., et al. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Experimental Hematology 2008, 36:997-1003.
177. Morgillo F., et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Research 2006, 66:10100-10111.
178. Munn D.H., Cheung N.K. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. The Journal of Experimental Medicine 1990, 172:231-237.
179. Nagorsen D., Baeuerle P.A. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Experimental Cell Research 2011, 317:1255-1260.
180. Nahta R., et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Research 2005, 65:11118-11128.
181. Ng Tang D., et al. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunology Research 2013, 1:229-234.
182. Niederfellner G., et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011, 118:358-367.
183. Niesner U., et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjugate Chemistry 2002, 13:729-736.
184. Nijhof I.S., et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica 2015, 100:263-268.
185. Nocentini G., et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:6216-6221.
186. Nocentini G., et al. Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. British Journal of Pharmacology 2012, 165:2089-2099.
187. Ocean A.J., et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial. Cancer 2012, 118:5497-5506.
188. Okamoto I., et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Science 2003, 94:50-56.
189. Okuda K., et al. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Science 2008, 99:2280-2285.
190. Olafsen T., et al. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biology: The Journal Of the International Society for Oncodevelopmental Biology and Medicine 2012, 33:669-677.
191. Oliner J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
192. Osada T., et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. British Journal of Cancer 2010, 102:124-133.
193. Ott P.A., et al. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2014, 32:3659-3666.
194. Overdijk M.B., et al. Crosstalk between human IgG isotypes and murine effector cells. Journal of Immunology 2012, 189:3430-3438.
195. Padera T.P., Jain R.K. VEGFR3: a new target for antiangiogenesis therapy?. Developmental Cell 2008, 15:178-179.
196. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer 2012, 12:252-264.
197. Park J.J., et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010, 116:1291-1298.
198. Paschold M.J.E.H., Lena H, et al. A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung can-cer (NSCLC). J Clin Oncol 2012, 30(15 (Suppl.)). (abstract 7584).
199. Pawluczkowycz A.W., et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. Journal of Immunology 2009, 183:749-758.
200. Paz-Ares L., et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. The Lancet. Oncology 2015, 16:328-337.
201. Pe al Feasibility and results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2014, 32(Suppl. 5s). (abstr 4026).
202. Pedretti M., et al. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. British Journal of Cancer 2010, 103:827-836.
203. Peggs K.S., et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. The Journal of Experimental Medicine 2009, 206:1717-1725.
204. Peipp M., et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008, 112:2390-2399.
205. Perrino E., et al. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Research 2014, 74:2569-2578.
206. Philips G.K., Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. International Immunology 2015, 27:39-46.
207. Postow M.A., et al. Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2015, 10.1200/JCO.2014.59.4358.
208. Powles V.N.T., Fine G.D., et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). Journal of Clinical Oncology: Official Journal of the American Society of Clinical 2014, 32(Suppl. 5s). (abstr 5011).
209. Prieto P.A., et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18:2039-2047.
210. Pro B., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30:2190-2196.
211. Quezada S.A., et al. CD40/CD154 interactions at the interface of tolerance and immunity. Annual review of immunology. 2004, 22:307-328.
212. Qureshi O.S., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603.
213. Racila E., et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:6697-6703.
214. Rader C. DARTs take aim at BiTEs. Blood 2011, 117:4403-4404.
215. Reck M., et al. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer. Lung Cancer 2013, 82:441-448.
216. Reddy B.K., et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncology 2014, 50:498-505.
217. Robak T., Robak E. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. Expert Opinion on Investigational Drugs 2014, 23:911-924.
218. Robert C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine 2011, 364:2517-2526.
219. Robert C., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
220. Robert C., et al. Nivolumab in previously untreated melanoma without BRAF mutation. The New England Journal of Medicine 2015, 372:320-330.
221. Rothe A., et al. Specific NK cell activation to treat relapsed/refractory (r/r) hodgkin lymphoma (HL) patients - final, updated data on clinical outcome, pharmacokinetics and pharmacodynamics of a phase 1 study investigating AFM13, a bispecific anti-CD30/CD16A Tandab. ASH Annual Meeting. Session: 624. Lymphoma: Therapy with Biologic Agents, Excluding Pre-Clinical Models: Poster I 2014.
222. Rudd C.E., et al. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunological Reviews 2009, 229:12-26.
223. Ruf P., et al. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. British Journal of Cancer 2007, 97:315-321.
224. Rybak J.N., et al. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Research 2007, 67:10948-10957.
225. Salgia R., et al. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2014, 20:1666-1675.
226. Sanderson R.J., et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2005, 11:843-852.
227. Schaer D.A., et al. Modulation of GITR for cancer immunotherapy. Current Opinion in Immunology 2012, 24:217-224.
228. Schanzer J.M., et al. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. The Journal of Biological Chemistry 2014, 289(July (27)):18693-18706. (PMID: 24841203). 10.1074/jbc.M113.528109.
229. Scheuer W., et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Research 2009, 69:9330-9336.
230. Schiff D., et al. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Investigational New Drugs 2015, 33:247-253.
231. Schliemann C., et al. Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Cancer Immunology Research 2015, 10.1158/2326-6066.CIR-14-0118.
232. Schneider-Merck T., et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. Journal of Immunology 2010, 184:512-520.
233. Schoeberl B., et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Research 2010, 70:2485-2494.
234. Schonfeld D., et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:8198-8203.
235. Sebastian M., et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunology, Immunotherapy: CII 2007, 56:1637-1644.
236. Segal A.S.N.H., Brahmer J.R., et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol 2014, 32(Suppl. 5s). (abstr 3002).
237. Sehouli J., et al. Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study. British Journal of Cancer 2014, 111:1519-1525.
238. Semac I., et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Research 2003, 63:534-540.
239. Shan D., et al. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunology, Immunotherapy: CII 2000, 48:673-683.
240. Sharkey R.M., et al. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Molecular Cancer Therapeutics 2011, 10:1072-1081.
241. Shibina A., et al. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. Journal of Molecular Medicine (Berlin, Germany) 2013, 91:459-472.
242. Shields R.L., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. The Journal of Biological Chemistry 2001, 276:6591-6604.
243. Shimamoto G., et al. Peptibodies: a flexible alternative format to antibodies. mAbs 2012, 4:586-591.
244. Shinojima N., et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Research 2003, 63:6962-6970.
245. Shor B., et al. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Molecular Immunology 2014, 10.1016/j.molimm.2014.09.014.
246. Shuptrine C.W., et al. Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology 2012, 22:3-13.
247. Sievers E.L., Senter P.D. Antibody-drug conjugates in cancer therapy. Annual Review of Medicine 2013, 64:15-29.
248. Skerra A. Lipocalins as a scaffold. Biochimica et Biophysica Acta 2000, 1482:337-350.
249. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Current Opinion in Biotechnology 2007, 18:295-304.
250. Skerra A. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. The FEBS Journal 2008, 275:2677-2683.
251. Slamon D.J., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
252. Smaglo B.G., et al. The development of immunoconjugates for targeted cancer therapy. Nature Reviews. Clinical Oncology 2014, 11:637-648.
253. Smith M.R., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. The New England Journal of Medicine 2009, 361:745-755.
254. Song H., Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Current Drug Delivery 2011, 8:26-44.
255. Spigel E.T.D.R., Ramlau R., et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29(Suppl. 15):7505.
256. Spratlin J.L., et al. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncology 2010, 6:1085-1094.
257. Stavenhagen J.B., et al. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Advances in Enzyme Regulation 2008, 48:152-164.
258. Steplewski Z., et al. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 1983, 221:865-867.
259. Stintzing S. Management of colorectal cancer. F1000Prime Reports 2014, 6:108.
260. Stockmeyer B., et al. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. Journal of Immunology 2000, 165:5954-5961.
261. Stolz C., Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leukemia & Lymphoma 2009, 50:873-885.
262. Sulica A., et al. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. International Reviews of Immunology 2001, 20:371-414.
263. Sullivan L.A., Brekken R.A. The VEGF family in cancer and antibody-based strategies for their inhibition. mAbs 2010, 2:165-175.
264. Sutherland M.S., et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. The Journal of Biological Chemistry 2006, 281:10540-10547.
265. Swain S.M., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Oncology 2013, 14:461-471.
266. Teeling J.L., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793-1800.
267. Terme M., et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Research 2011, 71:5393-5399.
268. Thomas D., et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. The Lancet. Oncology 2010, 11:275-280.
269. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012, 366:2443-2454.
270. Topalian S.L., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2014, 32:1020-1030.
271. Traini R., et al. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. Molecular Cancer Therapeutics 2010, 9:2007-2015.
272. Varfolomeev E., et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. The Journal of Biological Chemistry 2005, 280:40599-40608.
273. Vega M.I., et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15:6582-6594.
274. Vivek R., et al. Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy. ACS Applied Materials & Interfaces 2014, 6:6469-6480.
275. Vonderheide R.H., et al. CD40 immunotherapy for pancreatic cancer. Cancer Immunology, Immunotherapy: CII 2013, 62:949-954.
276. Wajant H. TRAIL and NFkappaB signaling-a complex relationship. Vitamins and Hormones 2004, 67:101-132.
277. Weiner G.J. Rituximab: mechanism of action. Seminars in Hematology 2010, 47:115-123.
278. Weiner L.M., et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews. Immunology 2010, 10:317-327.
279. Weiner L.M., et al. Antibody-based immunotherapy of cancer. Cell 2012, 148:1081-1084.
280. Weng W.K., Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001, 98:1352-1357.
281. Westin J.R., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. The Lancet. Oncology 2014, 15:69-77.
282. Winiarska M., et al. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Frontiers in Bioscience (Landmark Edition) 2011, 16:277-306.
283. Witzig T.E., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2002, 20:3262-3269.
284. WJ, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. European Society of Medical Oncology Congress 2014, (abstr 728).
285. Wolchok J.D., et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2013, 24:2174-2180.
286. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. The New England Journal of Medicine 2013, 369:122-133.
287. Woll P. Abstract B237: clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC). Molecular Cancer Therapeutics 2009, 8(B237).
288. Wong B.Y., Dang N.H. Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opinion on Biological Therapy 2010, 10:1251-1258.
289. Wu B., Sun Y.N. Pharmacokinetics of Peptide-Fc fusion proteins. Journal of Pharmaceutical Sciences 2014, 103:53-64.
290. Wurch T., et al. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends in Biotechnology 2012, 30:575-582.
291. Xu H., et al. Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody. Cancer Immunology Research 2015, 3:266-277.
292. Xu X., et al. Cancer nanomedicine: from targeted delivery to combination therapy. Trends in Molecular Medicine 2015, 10.1016/j.molmed.2015.01.001.
293. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nature Reviews. Molecular Cell Biology 2001, 2:127-137.
294. Younes A., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30:2183-2189.
295. Yu H., Rohan T. Role of the insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 2000, 92:1472-1489.
296. Yu P.A., Penuel W.E., et al. Exploratory biomarker analyses from OAM4558g: a placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29(Suppl.):7529.
297. Zeng Y., et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Molecular Immunology 2005, 42:1311-1319.
298. Zhu X., et al. COMBODY: one-domain antibody multimer with improved avidity. Immunology and Cell Biology 2010, 88:667-675.
299. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nature Reviews. Immunology 2009, 9:729-740.
300. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews. Immunology 2008, 8:467-477.